| Literature DB >> 21072040 |
R Domanico1, D K Davis, F Coleman, B O Davis.
Abstract
OBJECTIVE: To test the efficacy of single family room (SFR) neonatal intensive care unit (NICU) designs, questions regarding patient medical progress and relative patient safety were explored. Addressing these questions would be of value to hospital staff, administrators and designers alike. STUDYEntities:
Mesh:
Year: 2010 PMID: 21072040 PMCID: PMC3070087 DOI: 10.1038/jp.2010.120
Source DB: PubMed Journal: J Perinatol ISSN: 0743-8346 Impact factor: 2.521
NICU physical environments
| Particulates (>2 μm) | |||
| OPEN | 348 | 47 | 19 |
| SFR | 18 | 39 | 25 |
| CO2 (p.p.m.) | |||
| OPEN | 778 | 534 | 496 |
| SFR | 425 | 393 | 462 |
| Air temperature (°F) | |||
| OPEN | 73 | 72 | 72 |
| SFR | 72 | 72 | 72 |
| Relative humidity (%) | |||
| OPEN | 12 | 12 | 12 |
| SFR | 45 | 45 | 45 |
| Noise criterion (quiet) | |||
| OPEN | 50 | — | 55 |
| SFR | 35 | — | 35 |
| Noise criterion (busy) | |||
| OPEN | 55 | — | 50 |
| SFR | 35 | — | 35 |
| Noise Leq (dBA) 2000 Hz (quiet) | |||
| OPEN | 46 | — | 53 |
| SFR | 33 | — | 33 |
| Noise Leq (dBA) 2000 Hz (Busy) | |||
| OPEN | 51 | — | 48 |
| SFR | 32 | — | 34 |
| | |||
| OPEN | 7/1458 | 389 | 7 |
| SFR | 25/1652 | 374 | 25 |
Abbreviations: NICU, neonatal intensive care unit; OPEN, open-bay ward; SFR, single family room.
Location no. 1 nearest to entry/nursing station.
PEMRs 2 and 3 patient progress
| P | |||||||
|---|---|---|---|---|---|---|---|
| n | n | ||||||
| Race distribution | |||||||
| Caucasian | 72 | 71 | |||||
| Other | 3 | 4 | |||||
| Gestational age (weeks) | 75 | 34.0 | 34.0 | 75 | 34.0 | 34.0 | 0.935 |
| Small for gestational age | 0 | 2 | |||||
| Admission weight (g) | 75 | 2295 | 2295 | 75 | 2282 | 2282 | 0.919 |
| Weight range | 1030–4570 | 1010–3855 | |||||
| Acuity (PEMR) | 75 | 2.54 | 3.00 | 75 | 2.54 | 3.00 | 0.998 |
| Length of stay | 75 | 17.9 | 12.0 | 75 | 15.7 | 10.0 | 0.340 |
| Weight gain/day | 75 | −3.7 | −4.0 | 75 | −7.5 | −0.7 | 0.445 |
| Length gain/day | 75 | 0.12 | 0.12 | 75 | 0.07 | 0.08 | 0.165 |
| Head circumference gain/day | 75 | 0.04 | 0.05 | 75 | 0.05 | 0.04 | 0.865 |
| Interval to enteral feeding | 75 | 2.3 | 2.0 | 75 | 1.6 | 1.0 | *0.003 |
| Interval to MBM start | 34 | 2.9 | 3.0 | 32 | 1.6 | 1.0 | *<0.001 |
| Interval to formula start | 41 | 1.8 | 1.0 | 43 | 1.6 | 1.0 | 0.765 |
| Mean TPN days | 42 | 7.3 | 6.0 | 29 | 5.1 | 4.0 | *0.048 |
| TPN days/LOS | 42 | 0.32 | 0.26 | 29 | 0.17 | 0.13 | *0.004 |
| CMV days | 4 | 7.3 | 11.0 | 2.0 | 5.0 | 5.0 | — |
| Total CPAP days | 51 | 7.4 | 4.0 | 43 | 7.1 | 3.0 | 0.836 |
| CPAP days/LOS | 51 | 0.31 | 0.20 | 43 | 0.33 | 0.13 | 0.704 |
| Total apnea events | 73 | 29.3 | 7.5 | 68 | 12.5 | 0.0 | *<0.001 |
| Apnea events/day | 73 | 1.1 | 0.5 | 68 | 0.5 | 0.0 | *<0.001 |
| Total caffeine days | 70 | 10.3 | 0.0 | 69 | 7.5 | 0.0 | 0.172 |
| Caffeine days/LOS | 70 | 0.33 | 0.0 | 69 | 0.23 | 0.0 | 0.111 |
Abbreviations: CMV, conventional mechanical ventilation; CPAP, continuous positive airway pressure; GA, gestational age; LOS, length of stay; MBM, maternal breast milk; OPEN, open-bay ward; PEMR, Physician's Estimate of Mortality Risk; SFR, single family room; TPN, total parenteral nutrition.
*Mann–Whitney rank-sum significant difference (P⩽0.05).
LOS ⩾14 days.
Insufficient data.
GA ⩽36 weeks.
Apnea events/day=total apnea events /LOS-CMV days.
PEMR 4 patient progress
| P | |||||||
|---|---|---|---|---|---|---|---|
| n | n | ||||||
| Race distribution | |||||||
| Caucasian | 5 | 5 | |||||
| Other | 1 | 1 | |||||
| Gestational age (weeks) | 6 | 32.0 | 31.0 | 6 | 31.0 | 30.0 | 0.469 |
| Small for gestational age | 0 | 0 | |||||
| Admission weight (g) | 6 | 1993 | 1490 | 6 | 1617 | 1180 | 0.485 |
| Weight range | 1255–3740 | 740–4025 | |||||
| Acuity (PEMR) | 6 | 4.0 | 4.0 | 6 | 4.0 | 4.0 | 1.000 |
| Length of stay | 6 | 70.0 | 71.0 | 6 | 68.0 | 60.0 | 0.890 |
| Weight gain/day | 6 | 17.4 | 17.7 | 6 | 16.8 | 16.7 | 0.759 |
| Length gain/day | 6 | 0.15 | 0.14 | 6 | 0.13 | 0.13 | 0.467 |
| Head circumference/day | 6 | 0.11 | 0.11 | 6 | 0.10 | 0.10 | 0.699 |
| Interval to enteral feeding | 6 | 8.7 | 3.0 | 6 | 3.8 | 4.0 | 0.937 |
| Interval to MBM start | 1 | 3.0 | 3.0 | 3 | 4.6 | 4.5 | — |
| Interval to formula start | 5 | 9.8 | 3.0 | 3 | 3.0 | 3.0 | 0.571 |
| Mean TPN days | 6 | 17.7 | 16.0 | 6 | 18.5 | 12.5 | 0.818 |
| TPN days/LOS | 6 | 0.26 | 0.21 | 6 | 0.23 | 0.25 | 0.937 |
| CMV days | 1 | 11.0 | 11.0 | 3 | 4.0 | 5.0 | — |
| Total CPAP days | 6 | 40.2 | 44.5 | 6 | 31.3 | 36.0 | 0.589 |
| CPAP days/LOS | 6 | 0.57 | 0.66 | 6 | 0.50 | 0.65 | 0.937 |
| Total apnea events | 6 | 135.2 | 122.5 | 6 | 97.3 | 89.0 | 0.699 |
| Apnea events/day | 6 | 17.4 | 2.9 | 6 | 1.4 | 1.6 | 0.180 |
| Total caffeine days | 6 | 41.8 | 54.0 | 6 | 40.5 | 45.0 | 0.818 |
| Caffeine days/LOS | 6 | 0.59 | 0.77 | 6 | 0.61 | 0.83 | 0.937 |
Abbreviations: CMV, conventional mechanical ventilation; CPAP, continuous positive airway pressure; GA, gestational age; LOS, length of stay; MBM, maternal breast milk; OPEN, open-bay ward; PEMR, Physician's Estimate of Mortality Risk; SFR, single family room; TPN, total parenteral nutrition.
Insufficient data.
LOS ⩾14 days.
GA ⩽36 weeks.
Apnea events/day=total apnea events/LOS-CMV days.
Sustained lactation beyond 14 days
| P | |||
|---|---|---|---|
| Sustaining stage III lactation ( | 20 | 23 | |
| Discharged breastfeeding ( | 10/50% | 16/70% | |
| Mean days on MBMb | (20) 23.2/15.5 | (23) 34.4/33.0 | *0.031 |
| MBM days/LOS | (20) 0.66/0.69 | (23) 0.90/1.0 | *0.001 |
Abbreviations: LOS, length of stay; MBM, maternal breast milk; OPEN, open-bay ward; SFR, single family room.
*Mann–Whitney rank-sum significant difference (P⩽0.05).
(n) mean/median. bMaternal breast milk.
Nosocomial sepsis incidence
| 2 | 0 | |
| CONS | 6 | 2 |
| 0 | 1 | |
| 1 | 0 | |
| 1 | 1 | |
| 0 | 1 | |
| MRSA | 1 | 0 |
| 3 | 1 | |
| Total | 14 (11%) | 6 (6%) |
Abbreviations: CONS, coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; OPEN, open-bay ward; SFR, single family room.
Sensitive to first-tier antibiotics.
Resistant to first-tier antibiotics.